Traitement par lenalidomide dans la forme intracérébrale d’amylose AL
Sign Up to like & getrecommendations! Published in 2018 at "Revue Neurologique"
DOI: 10.1016/j.neurol.2018.01.347
Abstract: Introduction Distincte de l’angiopathie amyloide, l’amylose AL intracerebrale sans hemopathie est exceptionnelle. L’efficacite du lenalidomide dans cette indication n’a pas ete etudiee, nous rapportons 3 cas. Observation Trois femmes de 45, 56 et 64 ans presentaient des troubles… read more here.
Keywords: chez; lenalidomide dans; par lenalidomide; lenalidomide ... See more keywords
Development of thrombotic thrombocytopenic purpura during lenalidomide therapy: three new cases and review of literature
Sign Up to like & getrecommendations! Published in 2019 at "British Journal of Haematology"
DOI: 10.1111/bjh.16333
Abstract: Thrombotic thrombocytopenic purpura (TTP) is a rare and life-threatening thrombotic microangiopathy (TMA) syndrome (Kremer et al. 2017). TTP typically includes severe thrombocytopenia, microangiopathic hemolytic anemia (MAHA) with schistocytes and organ manifestations secondary to microvascular thrombosis… read more here.
Keywords: thrombocytopenic purpura; thrombotic thrombocytopenic; new cases; lenalidomide ... See more keywords
Lenalidomide-induced focal myocarditis mimicking acute ST segment elevation myocardial infarction
Sign Up to like & getrecommendations! Published in 2020 at "Postgraduate Medical Journal"
DOI: 10.1136/postgradmedj-2020-139107
Abstract: An 86-year-old woman with a history of hypertension and diabetes presented with left-sided chest pain and dyspnoea 2 weeks after her treatment for diffuse large B-cell lymphoma. She was treated with a chemo-free regimen with… read more here.
Keywords: segment; myocardial infarction; lenalidomide; segment elevation ... See more keywords
Abstract 2007: Evaluation of the antitumor activity of ca102l, a hyaluronic acid and lenalidomide conjugate, in multiple myeloma
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-2007
Abstract: Multiple Myeloma (MM) is a rare and incurable hematological malignancy. Despite emerging treatments, there is still an unmet medical need for novel therapeutics to target the inherent and acquired drug resistance associated with MM. CA102L… read more here.
Keywords: ca102l; hyaluronic acid; conjugate; multiple myeloma ... See more keywords
Lenalidomide and Vorinostat Maintenance after Autologous Transplant in Multiple Myeloma- Long Term Follow-up
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-116460
Abstract: Introduction: Post autologous transplant maintenance therapy with lenalidomide for patients with multiple myeloma (MM) is standard of care (McCarthy et al, NEJM, 2012). Vorinostat (SAHA, Zolinza) is a HDAC inhibitor and preclinical data suggested that… read more here.
Keywords: maintenance; autologous transplant; vorinostat; lenalidomide ... See more keywords
Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma.
Sign Up to like & getrecommendations! Published in 2021 at "Blood"
DOI: 10.1182/blood.2020007081
Abstract: Emergence of drug resistance to all available therapies is the major challenge to improving survival in myeloma. Cereblon (CRBN) is the essential binding protein of the widely used immunomodulatory drugs (IMiDs) and novel CRBN E3… read more here.
Keywords: myeloma; lenalidomide; multiple cereblon; resistance ... See more keywords
Self-reported adherence to lenalidomide as maintenance therpay for multiple myeloma after autologous stem cell transplantation.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.e20046
Abstract: e20046Background: Increase availability of oral anticancer drugs has raised concerns about patient adherence. In 2017, lenalidomide was approved as maintenance therapy for multiple myeloma (MM) aft... read more here.
Keywords: maintenance; lenalidomide; multiple myeloma; self reported ... See more keywords
PARP1 promotes tumor proliferation in lenalidomide-resistant multiple myeloma via the downregulation of microRNA-192-5p-AKT signaling
Sign Up to like & getrecommendations! Published in 2024 at "Translational Cancer Research"
DOI: 10.21037/tcr-24-1543
Abstract: Background Lenalidomide-based therapies are recommended as first-line treatment for multiple myeloma (MM) patients, regardless of the transplant eligibility. Resistance to lenalidomide is a clinical problem that urgently needs to be addressed. The expression of poly(ADP-ribose)… read more here.
Keywords: cell lines; parp1; lenalidomide; lenalidomide resistant ... See more keywords